Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
This nationwide study was successful at identifying patients and evaluating the efficacy of molecularly targeted therapy for rare molecular subgroups of patients in a histology-agnostic fashion. Unfortunately, there was no activity of samotolisib against tumors with PI3K/mTOR pathway alterations. Prospective trials such as the NCI-COG Pediatric MATCH are necessary to evaluate the efficacy of molecularly targeted therapies given their increasing use in clinical practice.
Authors
- Kathleen Ludwig
- Jin Piao (ORCID: https://orcid.org/0000-0003-0516-6280)
- Lauren Saguilig
- Joyce Mhlanga (ORCID: https://orcid.org/0000-0002-6136-265X)
- Sinchita Roy‐Chowdhuri (ORCID: https://orcid.org/0000-0002-9447-7701)
- Joel M. Reid (ORCID: https://orcid.org/0000-0003-2872-3123)
- David R. Patton (ORCID: https://orcid.org/0000-0003-3855-0166)
- D. Williams Parsons (ORCID: https://orcid.org/0000-0002-8775-3501)
- Nita L. Seibel (ORCID: https://orcid.org/0000-0001-6259-7955)
- Brenda J. Weigel (ORCID: https://orcid.org/0000-0003-1080-1402)
- Elizabeth Fox (ORCID: https://orcid.org/0000-0002-9998-5326)
- Katherine A. Janeway (ORCID: https://orcid.org/0000-0001-6000-3594)
- Margaret Mooney (ORCID: https://orcid.org/0000-0002-6998-8331)
- Todd A. Alonzo (ORCID: https://orcid.org/0000-0002-6772-6581)
- Brent D. Coffey (ORCID: https://orcid.org/0009-0009-2047-5699)
- James V. Tricoli (ORCID: https://orcid.org/0000-0003-3975-8516)
- Stacey L. Berg (ORCID: https://orcid.org/0000-0003-2832-9994)
- Naoko Takebe (ORCID: https://orcid.org/0000-0002-5790-4954)
- Douglas S. Hawkins (ORCID: https://orcid.org/0000-0003-3602-1375)
- Theodore Willis Laetsch (ORCID: https://orcid.org/0000-0002-8497-3138)
- P. Mickey Williams (ORCID: https://orcid.org/0000-0002-3309-5988)
Institutions
- University of Southern California (US)
- Seattle Children's Hospital (US)
- University of Minnesota (US)
- St. Jude Children's Research Hospital (US)
- Mayo Clinic (US)
- Children's Hospital of Philadelphia (US)
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Center for Information Technology (US)
- Dana-Farber Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Children's Oncology Group (US)
- National Cancer Institute (US)
- Children's Cancer Center (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
- Philadelphia University (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/po.24.00258
- Citations
- 4
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.94